We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
9.00 | 0.53% | 1,714.00 | 1,714.00 | 1,715.00 | 1,716.00 | 1,695.50 | 1,705.00 | 1,271,360 | 13:48:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.31 | 70.5B |
Date | Subject | Author | Discuss |
---|---|---|---|
31/1/2024 07:46 | A start, but dividend increase needed to be nearer 5% to drive the share price on from here, especially with Zantac litigation still ongoing. They need to deal with this. | cumnor | |
31/1/2024 07:39 | ..."With this progress made, GSK has today announced upgraded outlooks, from those previously given, for the period 2021-2026 and for 2031. For the period 2021-2026, GSK now expects sales to grow more than 7% on a CAGR basis and adjusted operating profit to increase more than 11%, on the same basis. This compares to previous outlooks of more than 5% and more than 10% respectively. Adjusted operating profit margin in 2026 is now expected to be more than 31%."Encouraging. | steeplejack | |
31/1/2024 07:29 | Happy with them Results, slight increase in the dividend as well. | igoe104 | |
31/1/2024 07:22 | Any views on the results? Seem pretty good reading to me | panache1 | |
30/1/2024 18:57 | When will actually hear the zantac verdict ? | alibizzle | |
30/1/2024 18:13 | You would think it may go up but, as you say, who knows..Guess good pipeline progress + rising sales + resolution of Zantac will be the turbocharge we need.. | rikky72 | |
30/1/2024 17:58 | If this goes down tomorrow time to load up and hold | mj19 | |
30/1/2024 10:34 | GSK Q4 ex div is 22 Feb 2024 | tradermichael | |
29/1/2024 16:06 | All the good news and GSK still going down | abdullla | |
29/1/2024 07:58 | GSK is expected to achieve blockbuster status for its months-old RSV vaccine this week, stealing a march on rival Pfizer and begin allaying long-standing investor concerns about its pipeline. More than a fifth of adults over 60 in the US have received a vaccine for respiratory syncytial virus — an infection with cold-like symptoms — in the months since GSK and US rival Pfizer rolled out the first vaccines across the US. GSK’s vaccine generated £709mn of sales in the third quarter of 2023. Analysts have predicted that it hit the $1bn milestone at which drugs become “blockbusters& | tradermichael | |
26/1/2024 16:40 | Results next week | abdullla | |
26/1/2024 14:22 | Encouraging but I would like to know if judge has ruled for plaintiff or GSK | alibizzle | |
26/1/2024 14:02 | Shore Capital has lifted its target price from 1,850p to 2,000p and kept a 'buy' rating. | tradermichael | |
26/1/2024 13:58 | A spokesman for GSK said: "We’re very confident in our position and continue to vigorously defend ourselves based on the facts and science of this litigation. Since 2019, there have been 15 peer-reviewed epidemiological studies on the effects of ranitidine use on humans which reflect the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk for any type of cancer. “In Delaware, GSK is arguing that the court should follow the federal MDL court’s comprehensive Daubert ruling which, based on the scientific evidence, effectively dismissed all cases and claims related to the federal case’s five designated cancers. Like the federal courts, Delaware state courts apply the Daubert standard to determine the admissibility of expert evidence. “The Delaware court are also considering the admissibility of evidence concerning five additional cancers, all of which should be rejected under the standards set by the MDL court, especially given that the MDL plaintiffs previously abandoned those claims due to a lack of scientific evidence." | tradermichael | |
26/1/2024 13:43 | Will we actually get any news about court case outcome from Delaware soon | alibizzle | |
26/1/2024 13:18 | 1700p or 1800p .... still under-priced! | tradermichael | |
26/1/2024 08:09 | Oops sorry.. 1700p | dplewis1 | |
26/1/2024 08:08 | Citigroup raises target price to 1800p from 1535p | dplewis1 | |
26/1/2024 07:27 | A return to the low 14's would tempt me to jump back in for a trade (or investment, if the trade goes wrong!) Not tempted at the current levels, personally. GLA. | lovewinshatelosses | |
25/1/2024 17:48 | Million dollar question...when is the time to top up more ? | panache1 | |
25/1/2024 16:43 | At latest.. I'm hoping this whole caboodle will be sorted a bit before July but let's see.. | rikky72 | |
25/1/2024 11:01 | >>Am I right in saying that the Delaware zantac ruling is going to take 6 months as stated in The Times>> SeekingAlpha article above says: The Daubert "hearing suggests a decision by end-Jul latest, so we envisage GSK likely reaching a global settlement in 1H for its share of liability, estimated to be up to $2-3.5bn, as all parties may prefer avoiding ongoing uncertainty and future legal costs," Jefferies analyst Peter Welford, who has a buy rating on GSK, wrote on a note on Thursday. | zho | |
24/1/2024 14:48 | Left hand wants to know what the right hand is doing. | abdullla | |
24/1/2024 13:46 | Am I right in saying that the Delaware zantac ruling is going to take 6 months as stated in The Times , so nothing decided this week ? | alibizzle |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions